What is the overall incidence of ceftriaxone‑induced seizures in adult patients, and how does it differ in those with severe renal impairment or on dialysis?

Overall Incidence of Ceftriaxone-Induced Seizures

The overall incidence of ceftriaxone-induced seizures in adult patients is extremely rare, but the risk increases substantially in patients with severe renal impairment (CrCl <30 mL/min) or those on dialysis, where neurological complications including seizures, encephalopathy, and nonconvulsive status epilepticus have been documented in case reports and small case series.

Incidence Data

The available evidence does not provide precise population-based incidence rates for ceftriaxone-induced seizures. However, the FDA drug label explicitly warns about neurological adverse reactions including encephalopathy, seizures, myoclonus, and nonconvulsive status epilepticus, particularly in the context of overdosage in patients with severe renal impairment 1.

In Patients with Normal Renal Function

• Ceftriaxone-induced encephalopathy and seizures are exceptionally rare in patients with normal renal function 2
• Isolated case reports exist, but this represents an extremely uncommon occurrence
• The drug is generally well-tolerated when dosed appropriately

In Patients with Severe Renal Impairment or Dialysis

The risk profile changes dramatically in renal failure:

• A retrospective study of cephalosporin-induced nonconvulsive status epilepticus identified 10 patients with renal failure who developed altered consciousness and continuous epileptiform EEG activity while on cephalosporins (including 2 on ceftriaxone) 3
• Symptoms typically began 1-10 days after starting treatment (mean 5 days) 3
• The general incidence of uremic seizures in kidney failure is approximately 10%, though this includes all causes, not just drug-induced 4
• Multiple case reports document ceftriaxone-induced encephalopathy specifically in dialysis patients 5, 6

Key Risk Factors for Ceftriaxone Neurotoxicity

Identify high-risk patients using these criteria:

1. Severe renal impairment (CrCl <30 mL/min) 1
2. End-stage renal disease on hemodialysis or peritoneal dialysis 5, 6
3. Combined hepatic and renal dysfunction 1, 3
4. Elderly patients (mean age 69 years in one series) 3
5. Inadequate dose adjustment for renal function 7

Clinical Presentation

Recognize these neurological manifestations:

• Progressive disorientation or agitation 3
• Altered consciousness without overt convulsions 3, 5
• Mild facial or limb myoclonus 3, 5
• Aphasia and loss of contact 2
• Chorea-like tongue movements 2
• Generalized tonic-clonic seizures (less common) 8
• Nonconvulsive status epilepticus - easily mistaken for metabolic encephalopathy 3

The clinical picture is difficult to differentiate from metabolic encephalopathy without EEG confirmation 3.

Dosing Considerations in Renal Impairment

Critical dosing guidance from FDA labeling:

• Patients with renal failure normally require no adjustment when usual doses are administered, as ceftriaxone has dual biliary and renal excretion 1
• However, in patients with both hepatic dysfunction and significant renal disease, ceftriaxone dosage should not exceed 2 grams daily 1
• Ceftriaxone is not removed by peritoneal or hemodialysis - no supplementary dosing is required following dialysis 1
• In patients with both severe renal and hepatic dysfunction, close clinical monitoring for safety and efficacy is advised 1

This creates a paradox: While standard dosing is recommended for isolated renal failure, the accumulation risk and documented neurotoxicity cases suggest heightened vigilance is essential.

Comparison with Other Cephalosporins

The evidence shows cephalosporin-associated encephalopathy is a class effect, with varying frequencies:

• Cefepime appears most commonly implicated (6 of 10 patients in one series) 3, 9, 7
• Ceftazidime (2 of 10 patients) 3
• Ceftriaxone (2 of 10 patients) 3
• Cefotaxime (rare case reports) 6

Management Algorithm

When ceftriaxone neurotoxicity is suspected:

1. Immediately discontinue ceftriaxone 1, 3, 2, 5
2. Obtain urgent EEG - look for continuous or intermittent bursts of generalized, high-voltage, 1-2 Hz sharp wave activity that resembles but differs from triphasic waves 3
3. Administer intravenous clonazepam - suppresses epileptiform activity completely or partially 3
4. Initiate antiepileptic therapy as clinically indicated 3
5. Provide supportive treatment - no specific antidote exists 1
6. Monitor closely - improvement typically occurs within 24 hours to 7 days after discontinuation 3, 2, 5

Note: Hemodialysis or peritoneal dialysis will not reduce drug concentrations in overdosage 1.

Clinical Pitfalls

Avoid these common errors:

• Mistaking nonconvulsive status epilepticus for uremic encephalopathy - always obtain EEG in altered mental status patients on ceftriaxone with renal failure 3
• Assuming normal dosing is safe in isolated renal failure - while FDA-approved, case reports demonstrate real risk 1, 5
• Delaying diagnosis - symptoms can begin as late as 10 days after treatment initiation 3
• Expecting immediate resolution - neurological recovery may take up to 7 days after drug discontinuation 3

Practical Recommendations

For patients with severe renal impairment or on dialysis requiring ceftriaxone:

• Consider alternative antibiotics when feasible 10
• If ceftriaxone is necessary, maintain maximum daily dose of 2 grams if concurrent hepatic dysfunction exists 1
• Educate patients and caregivers to report neurological symptoms immediately 1
• Maintain low threshold for EEG if any mental status changes occur 3
• Document informed consent regarding neurotoxicity risk in high-risk patients

The rarity of precise incidence data reflects both the uncommon nature of this adverse effect and likely underreporting, particularly of nonconvulsive presentations that may be attributed to other causes in critically ill patients with renal failure.